PSMA

Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.

PSMA-11 (HBED-CC-PSMA) detects prostate cancer recurrence and metastasis by binding to the extracellular structural domain of prostate-specific membrane antigen (PSMA).PSMA-11 is often used as a tracer of PSMA-expressing tumours in positron emission tomography (PET) scanning by intravenous injection of gallium Ga 68-labelled PSMA-11, Glu-urea-Lys(Ahx) molecule targeted and bound PSMA-expressing tumour cells. After internalisation, PSMA-expressing tumour cells could be detected on PET imaging.

PSMA I&T is a PSMA-targeting radiocompound that serves as a diagnostic agent for prostate-specific membrane antigen-targeted therapy, often coupled with radioactivity.

Glu-urea-Lys is a molecular scaffold that targets PSMA and can be used as a prostate cancer imaging agent to study prostate-specific membrane antigens.

Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation. Piflufolastat can be used to prepare piflufolastat F 18 (DCFPyL F-18).

DUPA (N,N''-Carbonylbis[L-glutamic acid]) is used as the targeting moiety to actively deliver DTX for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.

CS-0047390, also known as tert-Butyl-DCL, PSMA inhibitor, is a radiopaque peptide reagent.

Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody with potential anticancer activity that can be used to study prostate cancer.

DUPA(OtBu)-OH is a precursor of DUPA, which is used as a targeting moiety to actively deliver Docetaxel (DTX) for treating Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer, with PSMA showing high affinity for DUPA (Ki = 8 nM).

Glu-urea-Lys TFA (1025796-69-3 free base) is a PSMA inhibitor.

PSMA-ALB-56 is a PSMA-targeting radioactive ligand with antitumor activity, composed of glutamic urea PSMA binding entities, DOTA chelating agents, and albumin binders based on 4-(p-iodophenyl)- fragment or p(tolyl)- fragment.

Rosopatamab-MMAE is an antibody-drug conjugate (ADC) that combines a PSMA-targeted antibody with Monomethyl auristatin E (MMAE), specifically designed for prostate cancer research.